Data completeness
0/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DALGAN (dezocine) is an injectable analgesic in pre-launch development by AstraZeneca. Dezocine is a mixed opioid agonist-antagonist indicated for pain management via intravenous or intramuscular administration. The mechanism of action involves both agonist and antagonist activity at opioid receptors, distinguishing it from pure mu-agonists.
Pre-Launch
Early-stage product with undefined commercial trajectory; team size and structure remain fluid pending regulatory approval and market entry strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DALGAN is a pre-launch asset with no current job listings but significant opportunity for early-career professionals seeking to build ground-floor expertise in a new product launch. The small molecule injectable space and mixed agonist-antagonist class present a differentiated career path if dezocine achieves regulatory approval and successful market positioning.
Brand Manager
Worked on DALGAN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.